WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 05-Dec-2014 (Data received as of 1-Dec-2014)
Next overall update June 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 42'2501 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 36'9071 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 64'291  63'937  63'582  63'231  62'888  59'213  56'846  53'941 
Births 792  792  791  791  791  757  756  757 
Surviving infants 789  789  789  789  788  753  750  749 
Pop. less than 5 years 3'943  3'924  3'906  3'895  3'881  3'668  3'809  3'422 
Pop. less than 15 years 11'716  11'684  11'646  11'605  11'556  11'215  11'281  12'043 
Female 15-49 years 14'328  14'360  14'390  14'421  14'466  14'510  14'346  13'055 

Number of reported case

(Click for retrospective incidence data for France)
Diphtheria
Japanese encephalitis
Measles 272  14'949  5'048  1'541  10'000  1'244 
Mumps 17'400 
Pertussis 100 
Polio* 10 
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total) 10  14  26  33  208 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for France)
Vaccine year result method % card seen                                                
BCG          78  78  83  74 
DTP1          99 
DTP3          99  99  99  99  98  97  94 
HepB_BD         
HepB3          74  78  74  65  51  26 
Hib3          98  98  98  97  97  86 
JapEnc         
MCV          89  91  89  89  90  84  71 
MCV2          67  72  67 
PCV1          95  96 
PCV3          89  89  86  89 
Pol3          99  99  99  99  98  98  95 
Rota1         
Rota_last         
Rubella1          89  91  90  90 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for France)
BCG 83  74  80 
DTP1 99  99  99  99  99  99  97  92 
DTP3 99  99  99  99  98  97  94  79 
HepB3 74  74  74  65  51  26 
HepB_BD
Hib3 98  98  98  97  97  86 
MCV 89  89  89  89  89  84  71 
MCV2 67  67  67  70  72 
PnC3 89  89  89  89 
Pol3 99  99  99  99  98  98  95  80 
Rota_last

Number of districts in the country 101  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 0
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes Infant at risk
DTaPHibHepIPV 2, 4, 11 months; Yes
DTaPIPV 6 years; Yes
HPV 11-14 years + 2 months, + 6 months; Yes Girls
HepB 2, 4, 11 months; Yes
Influenza > 65 years; Yes infant and adults at risk
MMR 12, 16-18 months; Yes
MenC_conj 12 months; Yes
Pneumo_conj 2, 4, 11 months; Yes
Pneumo_ps > 5 years; Yes population at risk
TdaPIPV 11-13 years; Yes
Varicella 12-18 years; If no disease history . For specific at risk-groups only. 2 doses
YF 12 months, No french Guiana

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No     
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 101  101  101  100  100  100  100 
Nº districts with DTP3 coverage >=80% number 89 
% of districts with DTP3 coverage >=80% From 0 to 100% 88 
Nº districts with measles (MCV1) coverage >=95% number         NA   
% of districts with MCV1 coverage >=95% From 0 to 100%            

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes           
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR No  No    Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100%         10  10  10 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.